Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283382 · ClinicalTrials.gov registry record · Early Phase 1
Cannabidiol Effects on Learning and Anxiety
A Early Phase 1 study of Anxiety and Fear, sponsored by University of Connecticut.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT05283382: Recruiting Early Phase 1 study of Anxiety and Fear, sponsored by University of Connecticut.
NCT05283382 is a Early Phase 1 study of Anxiety and Fear that is actively recruiting participants, run by University of Connecticut. The registered enrollment target is 160 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (202% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283382, a Early Phase 1 study of Anxiety and Fear, is actively recruiting participants, sponsored by University of Connecticut.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.
Primary Outcome
Electrodermal response as measured by galvanic skin response electrodes that are attached to two of the fingers via sticker electrodes. These passively measure the conductance of the sweat glands on the fingers.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cannabidiol Oral Product
Study Locations (1)
Connecticut
- University of Connecticut - Storrs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2026-02 |
| Phase | Early Phase 1 |
What NCT05283382 shows while recruiting
NCT05283382 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (202% higher).
The record links to 1 condition, with Anxiety and Fear appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05283382 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05283382 about?
NCT05283382 is a clinical study titled "Cannabidiol Effects on Learning and Anxiety". To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be p...
What is the current status of trial NCT05283382?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 160 participants. The study started on 2024-10-30. Estimated completion is 2026-02.
What conditions does trial NCT05283382 study?
This clinical trial studies the following conditions: Anxiety and Fear.
What interventions are being tested in trial NCT05283382?
The interventions under investigation include: Placebo (OTHER), Cannabidiol Oral Product (DRUG).
Who is sponsoring clinical trial NCT05283382?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283382 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety and Fear
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05283382's enrollment target sits among peer trials
160 88th of 2000 higher than 1,907 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI